Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLCShun Lu, Suresh S. Ramalingam, Terufumi Kato et al.|New England Journal of Medicine|2024Cited by 291
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung CancerJames Chih‐Hsin Yang, Gongyan Chen, Filippo de Marinis et al.|Journal of Clinical Oncology|2024Cited by 137